BCM
CPRX

Brookstone Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Brookstone Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-33,506
Closed -$666K – 999
2024
Q3 		$666K Hold
33,506
– – 0.01% 618
2024
Q2 		$566K Hold
33,506
– – 0.01% 626
2024
Q1 		$534K Hold
33,506
– – 0.01% 614
2023
Q4 		$563K Buy
33,506
+38
+0.1% +$519 0.01% 573
2023
Q3 		$433K Sell
33,468
-3,439
-9% -$46K 0.01% 606
2023
Q2 		$455K Buy
36,907
+3,439
+10% +$49.5K 0.01% 603
2023
Q1 		$605K Sell
33,468
-50
-0.1% -$825 0.01% 552
2022
Q4 		$657K Buy
33,518
+49
+0.1% +$754 0.01% 530
2022
Q3 		$415K Buy
+33,469
New +$397K 0.01% 596
2021
Q3 		– Sell
-16,472
Closed -$91K – 741
2021
Q2 		$91K Buy
16,472
+1,082
+7% +$5.58K ﹤0.01% 694
2021
Q1 		$71K Buy
+15,390
New +$61.1K ﹤0.01% 493

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Brookstone Capital Management's CPRX Position: Q4 2024 in Review

Brookstone Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q4 2024, closing a stake of 33,506 shares — an estimated $666K sold.

Brookstone Capital Management first reported a position in CPRX in Q1 2021 and held it in 11 quarters. The position peaked at $666K in Q3 2024. 336 funds tracked by Wall St. Rank hold CPRX as of Q4 2024.

  • Brookstone Capital Management reported no remaining Catalyst Pharmaceutical position as of Q4 2024 after selling out during the quarter.
  • Brookstone Capital Management sold 33,506 Catalyst Pharmaceutical shares in Q4 2024, an estimated $666K.
  • Brookstone Capital Management first reported a position in Catalyst Pharmaceutical in Q1 2021 and held it in 11 quarters.
  • Brookstone Capital Management's Catalyst Pharmaceutical position peaked at $666K in Q3 2024.
  • 336 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2024.

Based on Brookstone Capital Management's 13F filing for Q4 2024, filed 13 Jan 2025.